Real-world evidence for regulatory decision-making: updated guidance from around the world

被引:11
|
作者
Burns, Leah [1 ]
Le Roux, Nadege [2 ]
Kalesnik-Orszulak, Robert [3 ]
Christian, Jennifer [4 ]
Dudinak, Jennifer [5 ]
Rockhold, Frank [6 ]
Khozin, Sean [7 ]
O'Donnell, John [1 ]
机构
[1] Bristol Myers Squibb, Worldwide Hlth Econ & Outcomes Res, Princeton, NJ 08540 USA
[2] Bristol Myers Squibb, Regulatory Intelligence, Boudry, Switzerland
[3] Bristol Myers Squibb, Global Regulatory Sci, Princeton, NJ USA
[4] Target RWE, Durham, NC USA
[5] Bristol Myers Squibb, Global Regulatory Sci, Summit, NJ USA
[6] Duke Clin Res Inst, Dept Biostat & Bioinformat, Durham, NC USA
[7] MIT, Cambridge, MA USA
关键词
real-world evidence; real-world data; regulatory decision-making; real-world evidence regulatory frameworks; real-world data quality methods; real-world study methods; health technology assessment; SCIENTIFIC ADVICE;
D O I
10.3389/fmed.2023.1236462
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Leveraging the value of real-world evidence (RWE) to make informed regulatory decisions in the field of health care continues to gain momentum. Improving clinical evidence generation by evaluating the outcomes and patient experiences at the point-of-care would help achieve the ultimate aim of ensuring that effective and safe treatments are rapidly approved for patient use. In our previous publication, we assessed the global regulatory landscape with respect to RWE and provided a review of the regional availability of frameworks and guidance through May 2021 on the basis of 3 key regulatory elements: regulatory RWE frameworks, data quality guidance, and study methods guidance. In the current review, we have updated and elaborated upon recent developments in the regulatory RWE environment from a regional perspective under the same 3 regulatory elements stated above. In addition, we have also included a new category on procedural guidance. The review also discusses the perceived gaps and potential opportunities for future development and harmonization in this field to support framework establishment in regions without pre-existing RWE policies. Additionally, the article reviews current developments of health technology assessment (HTA) bodies pertaining to RWE and discusses the status of evidentiary alignment among regulators and HTA agencies.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Real-world evidence to support regulatory decision making: New or expanded medical product indications
    Franklin, Jessica M.
    Liaw, Kai-Li
    Iyasu, Solomon
    Critchlow, Cathy W.
    Dreyer, Nancy A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 (06) : 685 - 693
  • [42] An Industry Perspective on Real-World Evidence in Regulatory Decision Making: An Example of Transparency in Pharmacoepidemiologic Research
    Weaver, James
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2020, 23 : 34S - 37S
  • [43] Real-world study: from real-world data to real-world evidence
    Wen, Yi
    TRANSLATIONAL BREAST CANCER RESEARCH, 2020, 1
  • [44] Real-World Data and Real-World Evidence in Regulatory Decision Making: Report Summary From the Council for International Organizations of Medical Sciences (CIOMS) Working Group XIII
    Hennessy, Sean
    Atsuta, Yoshiko
    Hill, Sanna
    Raego, Lembit
    Juhaeri, Juhaeri
    Council Int Org Med Sci CIOMS Working Grp X, III
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2025, 34 (03)
  • [45] Advancing regulatory science through real-world data and real-world evidence
    Cure, Pablo
    Fessel, Joshua P.
    Hartshorn, Christopher M.
    Steele, Scott J.
    JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 8 (01)
  • [46] Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making
    Nemeth, Bertalan
    Kamusheva, Maria
    Mitkova, Zornitsa
    Petyko, Zsuzsanna Ida
    Zemplenyi, Antal
    Dimitrova, Maria
    Tachkov, Konstantin
    Balkanyi, Laszlo
    Czech, Marcin
    Dawoud, Dalia
    Goettsch, Wim
    Hren, Rok
    Knies, Saskia
    Lorenzovici, Laszlo
    Maravic, Zorana
    Piniazhko, Oresta
    Zerovnik, Spela
    Kalo, Zoltan
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (04)
  • [47] Real-world data curation to transform medical investigation: Technology to reimagine the economics of evidence gathering and support regulatory decision-making
    Leibtag, Aaron
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2020, 23 : 44S - 47S
  • [48] COMMON THREADS: REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT (HTA) AGENCIESAVTM RECOMMENDATIONS ON REAL-WORLD EVIDENCE (RWE) USE IN DECISION-MAKING
    Jaksa, A.
    Gatto, N.
    Case, A.
    VALUE IN HEALTH, 2020, 23 : S315 - S316
  • [49] Randomized Trials vs Real-world Evidence How Can Both Inform Decision-making?
    Sheldrick, R. Christopher
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (16): : 1352 - 1353
  • [50] DOES REAL-WORLD EVIDENCE PLAY A ROLE IN DECISION-MAKING BY HTA BODIES FOR MEDICAL TECHNOLOGIES?
    Hartley, L.
    Gildea, L.
    Mordin, M.
    Long, J.
    D'Souza, V
    Kinderas, M.
    Ling, C.
    Warttig, S.
    VALUE IN HEALTH, 2023, 26 (12) : S434 - S435